Posts Tagged ‘Francisco Lozano’

Categories

Posted in:

Friday August 05th, 2016

A new animal model to study the potential of CD6 receptor as a therapeutic target for immune-mediated diseases

IDIBAPS researchers have developed, for the first time, an animal model to study the role of the CD6 protein, a T lymphocyte molecule involved in the susceptibility for developing autoimmune diseases. It is an animal model, a mouse, that does not express this protein and that will reveal its pathophysiological role in the context of immune-mediated diseases such as Multiple Sclerosis, psoriasis or rheumatoid arthritis. Dr. Francisco Lozano, head of the IDIBAPS team Immune receptors of the innate and adaptive system and Senior Consultant at the Immunology Department in Hospital Clínic, has coordinated the study published in the Journal of Experimental Medicine (JEM).

Read the rest of this entry »

Comments Closed
Thursday January 23rd, 2014

CD6 is a molecule of the immune system which could improve the treatment of sepsis

Sepsis is a generalized and exacerbated inflammatory reaction caused by a serious infection that could lead to multi-organ failure, shock and often death (30-50 % of cases). Increased antibiotic resistance, together with the fact that these drugs combat groups of bacteria but not the proinflammatory activity caused by them or their toxins, makes sepsis a disease orphan of effective therapies. A study published in the Journal of Infectious Diseases shows that CD6, a molecule from our own lymphocytes, could be an effective alternative or complement for antibiotics in cases of sepsis by both Gram-positive and Gram-negative bacteria, regardless they are resistant to antibiotics or producing lethal toxins. The work is the result of a academia-industry collaboration between the team led by Dr. Francisco Lozano, Senior Consultant at the Immunology Service of the Hospital Clínic and head of the IDIBAPS research team Immune receptors of the innate and adaptive system and at the University Barcelona, together with members of the R&D team at ImmunNovative Developments SL, a recently created spin-off which emerged based on patents generated by the aforementioned research group. The first authors of the study are Mario Martínez-Florensa and Marta Consuegra-Fernández.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday November 12th, 2013

TV3’s Telethon 2012 dedicated to cancer will fund seven IDIBAPS projects

The TV3 Telethon Foundation held this evening a ceremony at the Barcelona Biomedical Research Park, where they presented the projects selected to be funded by the TV3 Telethon 2012 (Marató de TV3), dedicated to cancer. This initiative, which combines scientific divulgation and fundraising, is an effort of the Catalan TV station which annually, since 1992, discovers the best of society and research institutions. In its last edition it collected over 12 milion euros, now distributed in 42 research projects which underwent a rigorous evaluation process. Here we present the seven IDIBAPS projects chosen to be funded.

Read the rest of this entry »

Comments Closed
Tuesday January 12th, 2010

Three spin-offs of Hospital Clinic selected at the First Healthcare Investment Forum Barcelona

forumhealthcare_foto_post2

The Official Medical College of Barcelona, Keiretsu Forum Barcelona and Barcelona Activa organized last November 4, 2009 the 1st Healthcare Investment Forum Barcelona’09, in collaboration with Biocat and other institutions. The objective of this forum was to contact young entrepreneurs in the health sector with projects in biotechnology, medical devices, health services and information technology with venture capital investors interested in this sector.

This first edition of the Forum was a success. Over 35 companies presented their projects, of which 12 were finally selected. Three of the finalists were submitted by Hospital Clinic:

Read the rest of this entry »

Comments Closed
Monday March 09th, 2009

The Journals PNAS and Gastrointestinal Endoscopy Acknowledge the Work of the Researchers of Hospital Clínic – IDIBAPS

Articles reconeguts a PNAS i Gastrointestinal Endoscopy

The number and quality of the articles signed by researchers from Hospital Clínic and IDIBAPS continues to grow. There have been 2 recent examples of how this work has been receiving considerable international recognition.

First, the prestigious journal Proceedings of the National Academy of Science (PNAS) dedicated a 2-page illustrated commentary on the print edition of an article that appeared online in mid-January. This underlines the relevance of the results presented in the article, which described the efficacy of CD5 protein to treat septic shock caused by fungi. This study was carried out in collaboration with Hospital del Mar, Universidad Complutense, Madrid, and East Tennessee State University and, together with previous complementary research by the team, could become the first effective response to fungal and bacterial septic shock. The study was coordinated by Dr. Francisco Lozano and the main authors were Dr. Jorge Vera and Dr. Rafael Fenutria.

Also, the journal Gastrointestinal Endoscopy, one of the most important journals worldwide in the area of gastroenterology, has congratulated the authors of research published in September 2008. The article became the 11th most viewed online through Sciencedirect. This study on the treatment of gastric vascular lesions was signed by Dr. Samuel Herrera and Dr. Josep M. Bordas (main authors) and by Dr. Antoni Castells.

Comments Closed
Thursday January 15th, 2009

The CD5 Molecule Helps to Combat Septic Shock Caused by Fungi

Dr. Francisco Lozano and Dr. Jorge Vera

Septic shock is a serious medical condition caused by an infection that spreads in an uncontrolled manner throughout the body via the circulatory system. It produces severe inflammatory symptoms with cardiovascular failure caused by particularly virulent bacterial or fungal toxins in the blood. It is the main cause of death in intensive care units, with a mortality rate of between 30% and 50% of patients who suffer from it.

Read the rest of this entry »

Comments Closed